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Abstract: 354 
Background: A needs assessment for patients with hidradenitis suppurativa (HS) will support 355 
advancements in multidisciplinary care, treatment, research, advocacy, and philanthropy. 356 
Objective: To evaluate unmet needs from the perspective of HS patients. 357 
Methods: Prospective multinational survey of patients between October, 2017 and July, 2018.  358 
Results: Majority (63.7%, n=827) visited a physician ≥5 times prior to receiving formal HS diagnosis. 359 
Mean delay in diagnosis was 10.2 years (+/- 8.9 years). Patients experienced flare daily, weekly, or 360 
monthly in 23.0%, 29.8%, and 31.1%, respectively. Most (61.4%, n=798) rated recent HS-related pain as 361 
moderate or higher, while 4.5% described recent pain to be worst possible. Access to dermatology was 362 
rated as difficult by 37.0% (n=481). Patients reported visiting the emergency department and hospital ≥5 363 
times for symptoms in 18.3% and 12.5%, respectively. An extreme impact on life was reported by 43.3% 364 
(n=563), and 14.5% were disabled due to disease. Patients reported high frequency of comorbidities, most 365 
commonly mood disorders. Patients were dissatisfied with medical or procedural treatments in 45.9% and 366 
34.5%, respectively. 367 
Limitations: Data was self-reported. Patients with more severe disease may have been selected.  368 
Conclusions: HS patients have identified several critical unmet needs that will require stakeholder 369 
collaboration to meaningfully address. 370 
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Introduction  371 
Hidradenitis suppurativa (HS), also known as acne inversa, is a potentially debilitating 372 
inflammatory disease that is linked to significant comorbidity burden1and overall mortality,1-3 and that is 373 
also known to have substantial impact on general health-related and skin-specific quality of life (QOL).4,5 374 
Its inherent unpredictability with respect to disease course and treatment response poses challenges for 375 
patients and physicians. The purpose of the Global Survey Of Impact and Healthcare Needs (Global 376 
VOICE) project was to evaluate unmet needs in HS from the perspective of patients with the goal of 377 
supporting awareness initiatives in public and medical sectors, multidisciplinary approaches to care, 378 
advances in treatment, development of the research agenda, as well advocacy and philanthropy efforts. 379 
Methods 380 
 Global affiliates from 27 institutions, most of which were HS referral centers, in 14 countries 381 
across four continents agreed to prospective recruitment of participants between October, 2017 and July, 382 
2018. All patients at the center were offered an opportunity to participate, and there was no selection for 383 
disease stage. The questionnaire distributed to participants was developed by content experts and by 384 
patients with the disease in their capacity as research partners. It comprised 50 questions designed to 385 
capture demographics, perspectives on diagnosis and care, pain and symptoms, life impact, comorbid 386 
conditions, and treatment. Life impact was assessed using a disease-specific QOL instrument called the 387 
Hidradenitis Suppurativa Quality of Life instrument (HiSQOL).5,6 This study received approval from the 388 
human subjects committee of the Feinstein Institute for Medical Research at Northwell Health. 389 
Statistical Analysis 390 
There were 1,927 surveys returned, of which 1,299 surveys met inclusion criteria of being 391 
completed by a patient diagnosed with HS by a licensed healthcare provider and having a response to all 392 
variables of interest. Complete case analysis was performed. Categorical variables were described as 393 
frequencies and percentages, while means (standard deviation) were used to describe continuous 394 
variables. We assessed association between self-reported delay in diagnosis and age using ANOVA.  395 
Results 396 
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Patient Characteristics 397 
Characteristics of Global VOICE participants are described in Table I. Participants were mostly 398 
from Europe (55.4%) and North America (38.0%), and were mostly aged less than 40 years (61.3%), 399 
female (84.9%), and white (80.6%). Participants looking for work reported being unemployed in 9.6% of 400 
cases, and another 14.5% reported being disabled and unable to work due to HS.  401 
Diagnosis and Care 402 
Mean age at onset of symptoms was 20.5 (+/- 9.3) years while mean age at diagnosis was 30.7 403 
(+/- 10.9) years. Mean delay from onset of symptoms to diagnosis was 10.2 years (+/- 8.9 years). The 404 
majority of participants visited a physician for symptoms ≥5 times (63.7%, n=827) or 3-4 times (17.4%, 405 
n=226) prior to receiving a formal HS diagnosis. For 54.4% of participants (n=707), diagnosis was made 406 
by a dermatologist. For 59.8% (n=777) of participants, a dermatologist was the main physician managing 407 
their HS. However, 37.0% (n=481) of participants rated access to their dermatologist as difficult or very 408 
difficult. For symptoms related to HS, participants reported visiting the emergency department >5 times 409 
(18.3%, n=238), 4-5 times (7.7%, n=100), 2-3 times (17.2%, n=224), and once (16.3%, n=212).For 410 
symptoms related to HS, participants reported having been hospitalized >5 times (12.5%, n=163), 4-5 411 
times (4.5%, n=59), 2-3 times (11.5%, n=149), and once (15.9%, n=206). 412 
Pain and Symptoms 413 
On the Numeric Rating Scale (NRS) for pain, 61.4% (n=798) of participants rated HS-related 414 
pain over the past week as moderate or higher (NRS score ≥5). Participants described worst possible pain 415 
(NRS score 10) in 4.5% (n=59) of cases. Only 9.0% (n=117) of participants described no pain (NRS score 416 
0) over the past week. Mean NRS score 5.0 (SD=2.8).  417 
Participants also described the following symptoms related to HS over the past week: drainage 418 
(71.8%, n=933); odor (53.8%, n=699), and fatigue (61.0%, n=793). A flare was experienced daily 419 
(23.0%, n=299), weekly (29.8%, n=387), or monthly (31.1%, n=404) in most participants. 420 
Life Impact 421 
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Table II lists items and corresponding impact on QOL for participants. Most participants 422 
reported that HS impacted their lives moderately (27.2%, n=353) or very much/extremely (43.3%, n=563) 423 
in the past week. 424 
Comorbid Conditions 425 
 Comorbid conditions among participants are described in Table III. Anxiety (36.2%) and 426 
depression (35.8%) were most frequently reported. Some other notable comorbid conditions reported 427 
were suicidal ideation or attempt (9.1%), infertility (5.7%), spondyloarthritis (5.5%), inflammatory bowel 428 
diseases (5.3%), substance abuse (3.6%), and sexual dysfunction (3.5%).  429 
Treatment 430 
Participants were dissatisfied or very dissatisfied with current treatment in 45.9% (n=596) of 431 
cases. Among those dissatisfied, reasons for dissatisfaction included poor efficacy (42.1%, n=547), 432 
undesirable side effects (18.9%, n=246), expense (10.5%, n=136), inconvenience (10.2%, n=132), and 433 
invasiveness (7.5%, n=98). With respect to procedural treatments, 29.3% (n=380) of participants reported 434 
feeling satisfied or very satisfied, while 34.6% (n=449) reported feeling dissatisfied or very dissatisfied. 435 
Level of optimism for having satisfactory control of symptoms within the next 3 months was low or very 436 
low in 45.9% (n=596). 437 
Table IV describes frequency of medical and procedural treatment among participants. Most 438 
frequent medical treatments included oral antibiotics (85.6%, n=1,112) and intralesional corticosteroid 439 
(24.9%, n=323). Participants used a biologic in 20.8% (n=270) of cases, with adalimumab being the most 440 
frequent (16.0%, n=208). Participants used anti-androgen therapy in 12.7% (n=165) of cases, with 441 
spironolactone being the most frequent (11.1%, n=144). An oral retinoid and traditional 442 
immunosuppressive medication was used by 14.1% (n=183) and 8.7% (n=113) of participants, 443 
respectively. Participants underwent procedural treatment in 82.8% (n=1,075) of cases. Most frequent 444 
procedures were incision and drainage (70.0%, n=909), excision (54.8%, n=712), laser hair removal 445 
(10.5%, n=136), and deroofing (9.0%, n=117).   446 
Discussion  447 
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 To the best of the authors’ knowledge, the analysis presented herein represents the largest and 448 
most comprehensive multinational study of patient perspectives on unmet needs in HS. A number of 449 
disease-related observations warrant discussion.  450 
While nearly all Global VOICE patients had at least high school level education, approximately 451 
10% were unable to find work. Approximately 15% also reported being disabled and unable to work due 452 
to their disease. Previous cohort studies have described frequent absences from work and inability to 453 
properly perform responsibilities, in some cases resulting in unemployment,7-9 and this has also result in a 454 
negative impact on personal finances.8 Indeed, HS patients were more often observed to have low 455 
socioeconomic status (SES) in recent population studies.10,11 While low SES may influence development 456 
of disease, the more likely directional relationship is that low SES, potentially by way of inability to 457 
acquire or maintain gainful employment, is a disease consequence. Direct and indirect socioeconomic 458 
impact of HS warrants further study. 459 
 Most patients visited a physician at least five times prior to receiving a diagnosis, and they 460 
experienced on average a 10-year delay to diagnosis. Diagnosis delay reported herein is substantially 461 
longer than a mean delay of 7.2 years which was observed in a previous multinational survey.12 462 
Dermatologists likely have an important role in reducing diagnosis delay in HS, and indeed a 463 
dermatologist ultimately provided the formal diagnosis for over half of patients in this analysis. A 464 
dermatologist was also the main physician managing the disease in approximately 60% of patients. Care 465 
by a dermatologist has been shown to provide greatest likelihood of initiating medical treatment for HS, 466 
as well as for escalating therapy over time.13 However, overall utilization of ambulatory dermatology 467 
encounters appears low, as only one in five HS patients in the US has an established relationship with a 468 
dermatologist.14 Notably, half also reported disease flares either daily or weekly, and more than 80% 469 
experienced flares at least monthly. And yet, more than one third rated access to a dermatologist as 470 
difficult or very difficult, despite most living in urban or suburban areas. Not surprisingly then, one in 471 
four and one in six patients also reported visiting the emergency department and having been hospitalized, 472 
respectively, at least 4-5 times for acute symptoms. Utilization of acute care facilities, for which disease-473 
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specific costs are high,15-18 may be reduced further with improved urgent access to dermatologists. Along 474 
with communicating the value of dermatologists in diagnosis as well as acute and ongoing management 475 
of HS, there may be a need to ensure timely access to a dermatologist with the goal of improving quality 476 
and cost of care.  477 
In an international delphi exercise to define the core outcome set for clinical trials in HS, patients 478 
selected pain as their most important symptom.19 Remarkably, nine in ten Global VOICE patients 479 
described recent pain associated with their disease, while six in ten rated this pain as moderate to worst 480 
possible. In another study, recent pain was reported by 77.5% of patients and was linked to a substantial 481 
decrease in QOL.20 Specifically, pain and discomfort have been shown to interfere with daily activities, 482 
work, school or leisure, and result in feelings of helplessness and dependency.21 Chronicity of pain may 483 
also be a significant factor related to misuse of substances, which was reported by approximately 4% of 484 
Global VOICE patients. In a previous population analysis, prevalence of substance use disorder among 485 
HS patients was also observed to be 4%.22 However, strategies for addressing HS-associated pain are not 486 
well established. If pain is addressed at all, there is likely to exist variations in pain management 487 
practices,23-25 which may contribute to substance abuse among HS patients. Development of appropriate 488 
and effective pain management strategies for HS patients represents a fundamental unmet need. The 489 
authors underscore that observations on substance abuse in this study should not further stigmatize 490 
patients who are afflicted with HS. Rather, our hope is that the medical community, including 491 
dermatologists, will further embrace and engage integrated care plans which comprehensively support 492 
their needs.  493 
In this analysis, a significant proportion of HS patients described a moderate to extreme, overall 494 
and domain specific impact on life related to disease. Our population assessment of life impact is 495 
supported further through detailed qualitative assessment within tertiary-center cohorts in which HS 496 
patients describe impairments in enjoyment and satisfaction with general activity; independence; self-497 
esteem and body image, stigmatization and isolation,6,7,21,26-30 as well as feelings of self-consciousness, 498 
embarrassment, shame, repulsion, or being unlovable related to malodorous drainage or visible areas of 499 
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involvement.31 Given the many ways the disease impacts QOL, it is not surprising that disease-related life 500 
impact appears to be more significant for HS patients compared to those with atopic dermatitis, psoriasis, 501 
acne vulgaris, alopecia, among other disorders of the integument.26,32-37 In consideration for the total well-502 
being of HS patients, evaluation and management should include addressing psychosocial aspects of the 503 
disease through interdisciplinary care with behavioral health professionals who can address mental health 504 
issues and support coping and resilience strategies.38,39 505 
More than 80% of Global VOICE patients report having a comorbid condition. This observation 506 
is supported by a growing body of literature which suggests that HS, as a chronic inflammatory disease, 507 
may represent a bridge to comorbid illnesses. In a recent analysis, HS patients were observed to have 508 
twice the overall comorbidity burden compared with patients who did not have HS, as well as a 509 
significantly greater burden compared to psoriasis patients.1HS is thought to have similar comorbidity 510 
burden to other systemic diseases including systemic lupus erythematosus, dermatomyositis, ankylosing 511 
spondylitis, and rheumatoid arthritis.1 Patients with HS who have Charlson Comorbidity Index (CCI) of at 512 
least 5 had approximately five times the risk of 5-year mortality compared to those with CCI score of 513 
zero. 514 
With more than one in three patients reporting depression and/or anxiety, mood disorders 515 
represented the most frequent comorbidity among Global VOICE patients. Prevalence of depression 516 
within HS cohorts at referral centers ranges between 19.5% and 41.6%.26,40-42 Population data exploring 517 
the association between HS and depression also indicates a significant burden of mood disorder.43-45 518 
Notably, approximately one in eleven patients in the current analysis also reported suicidal ideation or 519 
attempt, which represents an alarmingly high frequency, especially in the context of a known association 520 
between HS and completed suicide.46Mood disorders and suicidality among HS patients is likely 521 
explained by the physical and psychosocial effects of the disease which result in poor QOL and low 522 
optimism. Global VOICE patients described a number of additional comorbidities, which are further 523 
supported by other population-based analyses,includingacne,47 polycystic ovarian syndrome,48 pyoderma 524 
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gangranosum,49 inflammatory bowel disease,50-52 lymphomas,53 spondyloarthritis,54 metabolic disease,55-59 525 
obstructive sleep apnea,60 major adverse cardiac events,3 sexual dysfunction,61 substance abuse and 526 
chronic opioid use,22,62 and Down syndrome.63 Given a general lack of disease awareness in HS and of its 527 
comorbidities in medical communities, dermatologists may need to be proactive in making 528 
recommendations on relevant preventative and screening measures to interdisciplinary care teams. 529 
Nearly half of Global VOICE patients were dissatisfied with current treatments, most commonly 530 
because of perceived poor efficacy and undesirable side effects. One third was also dissatisfied with 531 
procedural treatments. Thus, it is not surprising that nearly half of patients expressed low optimism for 532 
having satisfactory control of symptoms in the near future. There is however growing enthusiasm in the 533 
medical community for addressing treatment as a fundamental unmet need in HS. Recent investigative 534 
efforts to understand pathogenesis in HS, including immunologic aberrations,64,65 genetic 535 
predispositions,66 and microbiome alteration67,68 have translated to therapeutic trials which show promise. 536 
The National Institute of Health’s database of clinical studies (accessible at www.Clinicaltrials.gov) 537 
describes 19 active or planned medical and procedural interventional trials in February, 2019. In 538 
alignment with drug development programs, there is also an international initiative to develop a core set 539 
of measures for trials in HS with the goal of improving measurement of disease activity and treatment 540 
response, as well as of comparing therapeutic effectiveness. To date, Hidradenitis Suppurativa Core 541 
Outcome Set Collaboration (HISTORIC), a section of the International Dermatology Outcome Measures 542 
(IDEOM) organization that is further supported by the department of dermatology at Zealand University 543 
Hospital and the Cochrane Skin Core Outcomes Set Initiative (CS-COUSIN), has reached global 544 
stakeholder consensus on the core set of domains for HS trials,69 and is working toward finalizing its core 545 
measures set, which include new instruments under development. Additionally, there are several 546 
searchable global medical and advocacy organizations in HS that facilitate peer-to-peer support, 547 
encourage scientific discovery, and support access to treatments. 548 
 There are important limitations to this analysis warranting consideration. Data was self-reported 549 
and may be subject to misinterpretation of questions and to recall bias. Since questionnaires were 550 
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administered through dermatology centers, patients with more active or severe disease may have been 551 
selected. While demographic characteristics of the surveyed cohort approximate those of other HS 552 
populations in North America and Europe,43,70-72 our sample is non-random and uncontrolled. As such, 553 
results with modest directionality may be difficult to interpret. Complete case analysis has the potential to 554 
bias results when patients with missing data differ systematically from patients without missing data. 555 
However, analysis of missing data among survey participants showed that patients excluded due to any 556 
missing data had similar characteristics and responses to patients included in the analysis. 557 
Through this study, we have augmented our understanding of existing needs for HS patients, and 558 
we have identified several unmet needs which require attention. Addressing unmet needs in HS (Table V) 559 
is likely to necessitate a shared vision of health for HS patients among all stakeholders including patients, 560 
experts, interdisciplinary physicians, scientists, industry, regulatory agencies, philanthropists, advocates, 561 
and policy makers.562 
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Table I: Demographics and Clinical Characteristics of Global VOICE participants (N=1,299) 738 
Demographics n (%) 
Age   
   18-30 years  368 (28.3) 
   31-40 years  428 (33.0) 
   41-50 years  317 (24.4) 
   51-60 years  151 (11.6) 
   61+ years  35 (2.7) 
Gender   
   Male  196 (15.1) 
   Female  1103 (84.9) 
Race (US, Canada only, n=479)  
   White 386 (80.6) 
   Black 65 (13.6) 
   Other 28 (5.8) 
Body Mass Index*  
   Underweight or Normal Weight (BMI <24.9) 269 (20.7) 
   Overweight (BMI 25.0-29.9) 306 (23.6) 
   Obese (BMI > 30.0) 724 (55.7) 
Tobacco Smoking Status   
   Active smoker 571 (44.0) 
   Former smoker 352 (27.1) 
   Never a smoker 376 (28.9) 
Highest Education Level Achieved  
   High school 464 (35.7) 
   College/university degree 550 (42.3) 
   Graduate school degree 210 (16.2) 
   None of the above 75 (5.8) 
Employment Status  
   Employed/Not looking for employment/Retired 985 (75.8) 
   Not employed, looking for work 125 (9.6) 
   Disabled, not able to work 189 (14.5) 
Marital Status  
   Single/Divorced 419 (32.3) 
   In a relationship/Married/Widowed 880 (67.7) 
Region  
   Europe 719 (55.4) 
   North America  493 (38.0) 
Othera 87 (6.7) 
Setting  
   Urban 629 (48.4) 
   Suburban 338 (26.0) 
   Rural 332 (25.6) 
Physician diagnosing HS  
   Dermatologist 707 (54.4) 
   Primary care 265 (20.4) 
   Surgeon 141 (10.9) 
   Obstetrician/Gynecologist 61 (4.7) 
   Acute care physician (Emergency Medicine or Hospitalist 54 (4.2) 
   Other type of physician 53 (4.1) 
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   Pediatrician 11 (0.8) 
   Endocrinologist 4 (0.3) 
   Urologist 3 (0.2) 
 739 
HS- hidradenitis suppurativa 740 
a – Includes Asia, Australia, Africa, and South America 741 
* Body Mass Index calculated from self-reported height and weight 742 
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Table II: Disease-related Quality of Life Impact Among Global VOICE Participants (N=1299) 
 Not relevant Not at all/slightly Moderately Very much / 
Extremely 
Cannot engage 
due to HS 
In the past one week, how much has your HS 
interfered with the following activities: 
     
   Walking  72 (5.5) 720 (55.4) 259 (19.9) 227 (17.5) 21 (1.6) 
   Reaching 243 (18.7) 745 (57.4) 123 (9.5) 173 (13.3) 15 (1.2) 
   Standing up  125 (9.6) 851 (65.5) 185 (14.2) 133 (10.2) 5 (0.4) 
   Sitting down  73 (5.6) 651 (50.1) 253 (19.5) 308 (23.7) 14 (1.1) 
   Sleeping 64 (4.9) 679 (52.3) 252 (19.4) 292 (22.5) 12 (0.9) 
   Laying down  74 (5.7) 820 (63.1) 213 (16.4) 189 (14.5) 3 (0.2) 
   Leisure  93 (7.2) 496 (38.2) 230 (17.7) 348 (26.8) 132 (10.2) 
   Toilet  99 (7.6) 823 (63.4) 180 (13.9) 196 (15.1) 1 (0.1) 
   Shower  58 (4.5) 735 (56.6) 245 (18.9) 258 (19.9) 3 (0.2) 
   Dressed  53 (4.1) 726 (55.9) 224 (17.2) 290 (22.3) 6 (0.5) 
   Hair removal  205 (15.8) 388 (29.9) 164 (12.6) 336 (25.9) 206 (15.9) 
   Antiperspirant  236 (18.2) 587 (45.2) 112 (8.6) 193 (14.9) 171 (13.2) 
   Getting around 88 (6.8) 735 (56.6) 202 (15.6) 239 (18.4) 35 (2.7) 
   Exercising 143 (11.0) 444 (34.2) 193 (14.9) 326 (25.1) 193 (14.9) 
   Housework  71 (5.5) 624 (48.0) 232 (17.9) 336 (25.9) 36 (2.8) 
   Providing care  316 (24.3) 583 (44.9) 156 (12.0) 207 (15.9) 37 (2.8) 
In the past one week, how much has your HS:       
   Influenced your ability to work or study 159 (12.2) 606 (46.7) 181 (13.9) 274 (21.1) 79 (6.1) 
   Limited the type of work or study you do 175 (13.5) 623 (48) 153 (11.8) 275 (21.2) 73 (5.6) 
   Decreased the amount of time you spent on 
   work or study 185 (14.2) 643 (49.5) 155 (11.9) 253 (19.5) 63 (4.8) 
   Caused you to use extra effort to do your 
   work or study  174 (13.4) 604 (46.5) 144 (11.1) 319 (24.6) 58 (4.5) 
In the past one week, how have your current or 
potential new HS lesions influenced: 
     
   Clothing choice to avoid discomfort 38 (2.9) 311 (23.9) 207 (15.9) 743 (57.2) N/A 
   Clothing choice to avoid visibility 
   of HS 101 (7.8) 463 (35.6) 141 (10.9) 594 (45.7) 
N/A 
   Clothing choice to avoid an HS 
Flare 54 (4.2) 383 (29.5) 193 (14.9) 669 (51.5) 
N/A 
In the past one week, how bothered have you      
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been by these HS symptoms: 
   Pain  18 (1.4) 446 (34.3) 315 (24.2) 520 (40.0) N/A 
   Fatigue  58 (4.5) 462 (35.6) 276 (21.2) 503 (38.7) N/A 
   Itch  39 (3.0) 526 (40.5) 303 (23.3) 431 (33.2) N/A 
   Flu-like  130 (10.0) 898 (69.1) 144 (11.1) 127 (9.8) N/A 
   Drainage  39 (3.0) 523 (40.3) 307 (23.6) 430 (33.1) N/A 
   Odor  44 (3.4) 697 (53.7) 228 (17.6) 330 (25.4) N/A 
   Skin tightness 48 (3.7) 554 (42.6) 268 (20.6) 429 (33.0) N/A 
   Red lumps or knots  25 (1.9) 319 (24.6) 301 (23.2) 654 (50.3) N/A 
In the past one week, how much has your HS 
caused you to feel: 
     
   Depressed  50 (3.8) 568 (43.7) 226 (17.4) 455 (35.0) N/A 
   Angry  57 (4.4) 610 (47.0) 211 (16.2) 421 (32.4) N/A 
   Embarrassed  69 (5.3) 532 (41.0) 213 (16.4) 485 (37.3) N/A 
   Irritable  55 (4.2) 578 (44.5) 225 (17.3) 441 (33.9) N/A 
   Anxious  89 (6.9) 605 (46.6) 204 (15.7) 401 (30.9) N/A 
   Lonely  91 (7.0) 713 (54.9) 154 (11.9) 341 (26.3) N/A 
   Withdrawn  77 (5.9) 422 (32.5) 169 (13.0) 631 (48.6) N/A 
In the past one week, how much has HS 
impacted your sexual activity: 
     
   Lack of desire  171 (13.2) 407 (31.3) 130 (10.0) 453 (34.9) 138 (10.6) 
   Embarrassment  177 (13.6) 354 (27.3) 138 (10.6) 529 (40.7) 101 (7.8) 
   Pain  187 (14.4) 437 (33.6) 144 (11.1) 427 (32.9) 104 (8.0) 
In the past one week, how much has your HS 
impacted your concentration (i.e., leisure, 
school or work):  
N/A 676 (52.0) 298 (22.9) 325 (25.0) N/A 
In the past one week, how much has your HS 
impacted your life:  
N/A 383 (29.5) 353 (27.2) 563 (43.3) N/A 
Copyright permission granted 
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Table III: Frequency of Self-reported Comorbidities Among Global VOICE Participants 
 
Comorbidity n =1299 (%) 
Anxiety 470 (36.2) 
Depression 465 (35.8) 
Obesity 456 (35.1) 
Acne 405 (31.2) 
Hypertension 194 (14.9) 
Polycystic ovarian syndrome* 157 (14.2) 
High cholesterol 146 (11.2) 
Disability 132 (10.2) 
Diabetes mellitus 117 (9.0) 
Suicidal ideation 103 (7.9) 
Infertility 74 (5.7) 
Spondyloarthritis 72 (5.5) 
Suicidal attempt 55 (4.2) 
Crohn’s disease 47 (3.6) 
Substance use 47 (3.6) 
Sexual dysfunction 46 (3.5) 
Alcohol abuse 33 (2.5) 
Ulcerative colitis 25 (1.9) 
Myocardial infarction 12 (0.9) 
Pyoderma gangrenosum 10 (0.8) 
Coronary artery disease 9 (0.7) 
Down syndrome 7 (0.5) 
None 232 (17.9) 
* Percent of female patients (n=1,103) 
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Table IV: Frequency of Current or Past Medical Treatments and Procedures Among Global 
VOICE Participants 
Medical Treatment n=1299 (%) 
Antibiotic, oral 1,112 (85.6) 
Intralesional corticosteroid 323 (24.9) 
Biologic 270 (20.8) 
     adalimumab 208 (16.0) 
     infliximab 106 (8.2) 
     etanercept 25 (1.9) 
     secukinumab 15 (1.2) 
     ustekinumab 16 (1.2) 
     Anakinra 10 (0.8) 
     ixekizumab 5 (0.4) 
Anti-Androgen   165 (12.7) 
     spironolactone 144 (11.1) 
     finasteride 26 (2.0) 
Retinoid, oral 183 (14.1) 
     isotretinoin 150 (11.5) 
     acitretin 49 (3.8) 
Immunosuppressive, traditional 113 (8.7) 
     methotrexate 88 (6.8) 
     cyclosporine 35 (2.7) 
     Mycophenolate mofetil 10 (0.8) 
Systemic, miscellaneous    92 (7.1) 
     dapsone 60 (4.6) 
     zinc   24 (1.8) 
     oral contraceptive pill     11 (0.8) 
     cannabis 5 (0.4) 
None 38 (2.9) 
Procedural Treatment 1,075 (82.8) 
     incision and draining 909 (70.0) 
     excision 712 (54.8) 
     laser hair removal 136 (10.5) 
     deroofing 117 (9.0) 
     CO2 laser treatment 84 (6.5) 
     photodynamic therapy 13 (1.0) 
None 224 (17.2) 
*Sum of counts for individual medications may exceed the overall count for that category if a patient 
reported use of multiple medications within a category. 
32 
 
32 
 
Table V. Addressing Unmet Needs in Hidradenitis Suppurativa 
Domain Unmet Need Mechanisms to Address Needs 
Diagnosis 
and Care 
Disease awareness ●Promote advocacy and interdisciplinary education through patient support groups and 
medical organizations; Research and peer-reviewed publication. 
Delay in diagnosis ●Develop a point of care diagnostic aid which facilitates distinction from abscess or inflamed 
epidermal cysts by non-dermatologists. 
●Promote the role of the dermatologists in diagnosis and management. 
Quality and cost of care ●Improve dermatology access to manage disease flares. 
Symptoms Control of symptoms ●Develop appropriate and effective management strategies to address pain, drainage, odor, 
fatigue and flare 
Life Impact  Assessment of life impact ●Develop a disease-specific quality of life instrument to measure life impact 
Mental wellness ●Address psychosocial impact of the disease through interdisciplinary care with mental 
health professionals and advocates of well-being 
Comorbid 
Conditions 
Associated diseases ●Advance research to identify associated conditions, their related mechanisms, and their 
modification with treatment 
●Develop guidelines on evidence-based recommendations for prevention and screening of 
associated conditions 
●Establish interdisciplinary care teams to provide comprehensive care 
Treatment Safe and effective treatment ●Develop reliable and feasible tools to measure disease 
●Develop relevant outcome measures to assess efficacy of treatments 
●Advance research to identify disease mechanism and potential therapeutic targets  
●Develop medical treatments with improved efficacy and safety profiles  
●Evaluate outcomes for procedural treatments 
●Develop guidelines for pain management  
 
